Search

everythinglearnresearchcommunity

for

Search:↓

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

A user on dutasteride and oral minoxidil for two years has experienced worsening hair loss and an itchy scalp. Suggestions include increasing medication doses, trying other treatments like RU58841, getting a scalp biopsy, and addressing potential inflammation through diet and topical treatments.

The conversation discusses the use of KX826 for hair loss, with mixed opinions on its effectiveness. Some users are skeptical, mentioning no significant progress or regrowth, and others suggest it might be a scam or that data may be manipulated.

KX-826 shows promise for hair maintenance at higher doses with minimal side effects, despite failing Phase III trials. The user believes it is more effective than Minoxidil, Finasteride, and RU58841.

The user is seeking an alternative to DualGen 15 that includes Minoxidil and Retinol but is less sticky and more convenient to use. They find the current product inconvenient due to its stickiness and long wait time before washing.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

The conversation is about a 23-year-old who started treating their hair loss with daily oral dutasteride (0.5mg), oral minoxidil (2.5mg), topical RU58841 (80mg), and weekly microneedling at 1.5mm after seeing others' success stories. Significant improvements have been noted, and there is optimism for even better results in the next 6 months.

The user experienced severe scalp itching and hair loss while on dutasteride, which they linked to caffeine and masturbation. They plan to cut out both to see if their hair density improves.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Users inquire about experiences with Pyrilutamide Kx group buys.

The conversation discusses hair loss treatments, specifically the use of finasteride, minoxidil, and microneedling over 21 months. A user inquires about whether minoxidil is used orally or topically.

The conversation discusses hair regrowth progress using topical dutasteride with cetirizine, laser therapy, and growth serum. The user observes miniaturized, vellus hairs on the scalp.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.

The conversation discusses a hair loss treatment regimen involving high doses of dutasteride, finasteride, and minoxidil, with concerns about safety and potential side effects. Users advise against the excessive use of these medications, suggesting more moderate approaches and consulting a doctor.

The results of using Pyrilutamide, a hair loss treatment available on the gray market, and other treatments such as Minoxidil, Finasteride and RU58841.

Alfatradiol is discussed as a weak 5ARI and estrogen, not as effective as minoxidil, RU58841, or CB-03-01, but a safe alternative for those who can't use finasteride. Users express frustration over the lack of strong FDA-approved topical antiandrogens for hair loss.

The conversation is about using topical tazarotene with minoxidil for hair loss treatment. A user suggests using a lower strength than 0.025% for daily application.

KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.

The conversation is about incorporating tretinoin into a hair loss regimen after using minoxidil and finasteride for years, with discussions on the effectiveness of minoxidil and the potential benefits of adding tretinoin. Users also discuss the effectiveness of oral minoxidil and other topical treatments like diclofenac and fluocinolone.

The user has been using dutasteride, oral minoxidil, and vitamin D for 8 months with no improvement in hair loss. They are considering trying RU58841 or a hair transplant due to the ineffectiveness of current treatments.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

The conversation discusses the effectiveness of anti-androgens for hair loss, with a preference for topical treatments like RU58841 over oral options due to better scalp concentration and fewer side effects. Topical finasteride at 0.1% may provide some results, especially when combined with a topical androgen receptor antagonist like RU58841.

The user reports progress in hair regrowth using topical finasteride/minoxidil, microneedling, topical dutasteride, latanoprost, and MSM supplements. They express frustration over the lack of interaction on progress posts compared to trivial topics.

The user experienced hair regrowth with Minoxidil but noticed some hair loss after stopping microneedling for two months. They are hesitant to use finasteride again due to side effects and are considering other DHT blockers.

The user has been using Dutasteride, Minoxidil, Ketoconazole, and RU58841 for hair loss but sees subpar results. Suggestions include adjusting treatments, considering a hair transplant, and addressing scalp inflammation.

Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.

A user is starting treatment for hair loss with topical minoxidil, oral finasteride, and is considering adding topical latanoprost but is unsure about the application frequency and method for latanoprost. They are seeking advice from others with experience using these treatments.

RU and Pyri block androgen receptors to prevent hair loss but may also hinder hair regrowth since they prevent testosterone, which can stimulate hair growth, from binding to these receptors. The user is questioning if this understanding is correct.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.